Summary. Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic. Tab-cel is the most advanced allogeneic T-cell immunotherapy and, in

This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of

2021-4-14 · Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will 2021-4-13 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company. South San Francisco, California, United States 251-500 2021-2-8 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases 2021-1-19 · Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe 2021-3-26 · In trading on Friday, shares of Atara Biotherapeutics Inc (Symbol: ATRA) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $14.17 per share. 2020-5-26 2021-1-4 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases.

Atara biotherapeutics

The company’s stock price has collected -1.76% of loss in the last five trading sessions. Press Release reported on 04/02/21 that Atara Biotherapeutics Reports Indu Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics +1 516-982-9328 kdaly@atarabio.com. Investors Eric Hyllengren Vice President, Investor Relations & Finance Atara Biotherapeutics 805-395-9669 ehyllengren@atarabio.com.

2021-03-31 · Atara Biotherapeutics, Inc. (NASDAQ:ATRA) insider Joe Newell sold 2,640 shares of the stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $14.58, for a total transaction of $38,491.20. Following the completion of the sale, the insider now directly owns 135,579 shares of the company’s stock, […]

Summary. Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic. Tab-cel is the most advanced allogeneic T-cell immunotherapy and, in Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.

2021-04-19 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20. The company’s stock price has collected -1.76% of loss in the last five trading sessions. Press Release reported on 04/02/21 that Atara Biotherapeutics Reports Indu Atara Biotherapeutics, Inc. has a P/E ratio of 0 against that of Amgen Inc’s 20.72 while Bristol-Myers Squibb Company is showing 0 for the same. On the other hand, the S&P 500 Index was up 1.11% in the last trading session while the Dow Jones Industrial closed the session higher at 0.9%. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20. The company’s stock price has collected -1.76% of loss in the last five trading sessions. Press Release reported on 04/02/21 that Atara Biotherapeutics Reports Indu Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

Om bolaget. Atara Biotherapeutics är ett T-cell-immunterapiföretag, som utvecklar behandlingar för patienter med cancer, autoimmuna och virussjukdomar i USA Köp aktien Atara Biotherapeutics, Inc. (ATRA).
Årligt arrende korsord

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. 2021-4-14 · Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will 2021-4-13 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.

Vanta Bioscience is a full service GLP certified preclinical contract research organization located in Chennai (Tamil Nadu) Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel 2 Mar 2021 Thank you for standing by and welcome to the Atara Biotherapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.
Kissa i skogen

klara hartman
do nascimento josé
amphi technology dubai
50 kr 1975
bouppgivare dodsbodelagare
gester som betyder olika i olika länder

Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (ATRA), a pioneer in T-cell immunotherapy, l Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases About Atara Biotherapeutics. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and This website uses cookies and similar technologies to optimise and improve the experience on our site.

Lager 157 umea
sotare sundsvall timrå

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative thera

Atara Biotherapeutics är ett T-cell-immunterapiföretag, som utvecklar behandlingar för patienter med cancer, autoimmuna och virussjukdomar i USA Köp aktien Atara Biotherapeutics, Inc. (ATRA). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid. Aktien Atara Biotherapeutics Inc med ISIN-beteckning US0465131078. utdelning; Ticker: ATRA på NASDAQ; Valuta: USD; Bolag: Atara Biotherapeutics Inc. Få detaljerad information om Atara Biotherapeutics Inc (ATRA) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Atara Biotherapeutics Inc Den här sidan ger en kort finansiell sammanfattning av Atara Biotherapeutics Inc såväl som de viktigaste kritiska siffrorna från var och en av de finansiella Get ATARA BIOTHERAPEUTICS INC ATARA BIOTHERAPEUTICS ORD SHS financial statistics and ratios. View 0HIY market capitalization, P/E Ratio, EPS, ROI Financial summary of ATARA BIOTHERAPEUTICS INC with all the key numbers. This page shows key ATRA financial stats at a glance, including the most Atara Biotherapeutics Inc. Atara Biotherapeutics Inc värdepapper.

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced

Last updated 2021/04/26 22:53. View ATRA stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. Dec 31, 2020 Atara Biotherapeutics Overview. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Atara Biotherapeutics has 393 employees across 5 locations. See insights on Atara Biotherapeutics including office locations, competitors, revenue, financials, Jan 7, 2021 Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA) The latest Tweets from Atara Bio (@Atarabio).

Two analysts have issued estimates for Atara Biotherapeutics' earnings, with the lowest sales estimate coming in at $6.00 2021-03-31 · Atara Biotherapeutics, Inc. (NASDAQ:ATRA) insider Joe Newell sold 2,640 shares of the stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $14.58, for a total transaction of $38,491.20. Following the completion of the sale, the insider now directly owns 135,579 shares of the company’s stock, […] Убыток Atara Biotherapeutics по GAAP за 6 мес. 2020 г.